Fertility and Pregnancy-Related Issues in Young BRCA Carriers With Breast Cancer.

IF 1.8 Q3 ONCOLOGY

Breast Cancer : Basic and Clinical Research Pub Date : 2024-06-14 eCollection Date: 2024-01-01 DOI:10.1177/11782234241261429

Isotta Martha Magaton, Luca Arecco, Elene Mariamidze, Kristina Jankovic, Mihaela Stana, Giulia Buzzatti, Lucia Trevisan, Graziana Scavone, Silvia Ottonello, Piero Fregatti, Claudia Massarotti, Michael von Wolff, Matteo Lambertini

{"title":"Fertility and Pregnancy-Related Issues in Young BRCA Carriers With Breast Cancer.","authors":"Isotta Martha Magaton, Luca Arecco, Elene Mariamidze, Kristina Jankovic, Mihaela Stana, Giulia Buzzatti, Lucia Trevisan, Graziana Scavone, Silvia Ottonello, Piero Fregatti, Claudia Massarotti, Michael von Wolff, Matteo Lambertini","doi":"10.1177/11782234241261429","DOIUrl":null,"url":null,"abstract":"Approximately 10% to 15% of breast cancer cases in young women are diagnosed in patients harbouring germline (g) pathogenic or likely pathogenic variants (PVs) in the BReast CAncer 1 (BRCA1) or BReast CAncer 2 (BRCA2) genes. Preclinical and clinical studies showed a potential negative effect of germline BRCA1/2 (gBRCA1/2) PVs on ovarian reserve and reproductive potential, even before starting anticancer therapies. The aim of this article is to summarize the current literature on the fertility potential of young gBRCA1/2 PVs carriers with breast cancer and the risk of gonadotoxicity associated with anticancer treatments. Moreover, we describe the available evidence on the efficacy of fertility preservation techniques in young gBRCA1/2 PVs carriers and the safety data on having a pregnancy after breast cancer treatment.","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"18 ","pages":"11782234241261429"},"PeriodicalIF":1.8000,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11179469/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer : Basic and Clinical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/11782234241261429","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Approximately 10% to 15% of breast cancer cases in young women are diagnosed in patients harbouring germline (g) pathogenic or likely pathogenic variants (PVs) in the BReast CAncer 1 (BRCA1) or BReast CAncer 2 (BRCA2) genes. Preclinical and clinical studies showed a potential negative effect of germline BRCA1/2 (gBRCA1/2) PVs on ovarian reserve and reproductive potential, even before starting anticancer therapies. The aim of this article is to summarize the current literature on the fertility potential of young gBRCA1/2 PVs carriers with breast cancer and the risk of gonadotoxicity associated with anticancer treatments. Moreover, we describe the available evidence on the efficacy of fertility preservation techniques in young gBRCA1/2 PVs carriers and the safety data on having a pregnancy after breast cancer treatment.

查看原文本刊更多论文

患有乳腺癌的年轻 BRCA 携带者的生育和妊娠相关问题。

在年轻女性的乳腺癌病例中，约有 10%-15%的患者被诊断出携带乳腺癌基因 1（BRCA1）或乳腺癌基因 2（BRCA2）的种系（g）致病变体或可能致病变体（PVs）。临床前和临床研究表明，即使在开始接受抗癌治疗之前，种系 BRCA1/2 (gBRCA1/2) PVs 对卵巢储备和生殖潜能也有潜在的负面影响。本文旨在总结目前有关年轻乳腺癌 gBRCA1/2 PVs 携带者生育潜能以及抗癌治疗相关性腺毒性风险的文献。此外，我们还介绍了有关年轻的 gBRCA1/2 PVs 携带者生育力保存技术疗效的现有证据，以及乳腺癌治疗后怀孕的安全性数据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Breast Cancer : Basic and Clinical Research ONCOLOGY-

CiteScore

5.10

自引率

3.40%

发文量

审稿时长

8 weeks

期刊介绍： Breast Cancer: Basic and Clinical Research is an international, open access, peer-reviewed, journal which considers manuscripts on all areas of breast cancer research and treatment. We welcome original research, short notes, case studies and review articles related to breast cancer-related research. Specific areas of interest include, but are not limited to, breast cancer sub types, pathobiology, metastasis, genetics and epigenetics, mammary gland biology, breast cancer models, prevention, detection, therapy and clinical interventions, and epidemiology and population genetics.